
Consensus Statement: Medical Device Registries

Members-Only Webinar Wednesday 1st March 2017





APACMed Medical Device Registry Webinar Series: Introduction

- First in a series of three webinars on this topic
 - <u>WEBINAR One</u>: *Introduction and Overview*
 - <u>WEBINAR Two</u> [6th April]: *Medical Device Registry Guiding Principles*
 - <u>WEBINAR Three</u> [7th June]: *Future of Medical Device Registries*
- Webinar hosted by APACMed Medical/Clinical Affairs Committee

• Amit J. Shanker, MD, FACC, FHRS

Chair, APACMed Medical Affairs Committee Chief Medical Officer, Boston Scientific *Asia, Australia, Middle East and Africa*

• Laurent Metz, MD, MBA

Vice-Chair, APACMed Medical Affairs Committee HEMA CoE Lead, Medical Devices Asia Pacific, Johnson & Johnson Medical Asia Pacific



Today's Agenda

Introduction

- What is a Medical Device Registry?
- Overview of Medical Device Registries across the world
- Why will Medical Device Registries become more important in our region?

• Value of the Consensus Statement

- Why do we need a Consensus Statement?
 - Region-specific considerations mandating the need for a Consensus Statement

Implementation

- How can our members use this Consensus Statement?
- Next steps

Audience Participation: Question & Answer

Medical Device Registries

- Official definition from world health agencies
- How do registries differ from a defined clinical study?

Registry		Post-market study
1	An organized system to collect uniform data (clinical and other).	An organized project / plan to collect uniform data (clinical and other).
2	Include everyone (where possible) having the defined disease, condition, or exposure where there is very few (if any) selection criteria); criteria are set at the study level.	Include participants that satisfied a more narrow set of eligibility criteria.
3	Several independent studies may be planned or organized around the dataset available.	Single study with limited scope to expand beyond the study itself.
4	Focus is on the patients and usually non-product specific.	Focus is usually on specific products or a much more narrow target scope.
5	Large dataset (sample size) collected over a long period of time and may not have an end date.	Smaller dataset with defined end date.
6	Typically funded by non-commercial entities.	Funded by both commercial and non-commercial entities.
7	Always an observational study design.	Use observational or interventional study design. Not all observational studies are registry studies.
8	Registry study can be considered a post-market study.	Post-market study includes but not limited to registry study.


Clinical Registries

A Clinical Registry is <u>an organized system for the</u> <u>collection, storage, retrieval, analysis, and</u> <u>dissemination of information on individual</u> <u>persons*</u>

Well-designed and well-executed clinical registries provide insights into <u>safety</u>, <u>clinical outcomes</u>, <u>comparative effectiveness</u>, <u>and cost effectiveness</u>.

The observational design of registries provides

- a) Standardized information about a group of patients who share a condition or experience
- b) Insights in the results of a therapy in realworld practice, and ,
- c) More representative quality-of-life information



Volume 1

Registries for Evaluating Patient Outcomes:

Effective Health Care Program

A User's Guide





ed ASIA PACIFIC MEDICAL TECHNOLOGY ASSOCIATION

Medical Device Registries


- Official definition from world health agencies
- How do registries differ from a defined clinical study?

Registry		Post-market study
1	An organized system to collect uniform data (clinical and other).	An organized project / plan to collect uniform data (clinical and other).
2	Include everyone (where possible) having the defined disease, condition, or exposure where there is very few (if any) selection criteria); criteria are set at the study level.	Include participants that satisfied a more narrow set of eligibility criteria.
3	Several independent studies may be planned or organized around the dataset available.	Single study with limited scope to expand beyond the study itself.
4	Focus is on the patients and usually non-product specific.	Focus is usually on specific products or a much more narrow target scope.
5	Large dataset (sample size) collected over a long period of time and may not have an end date.	Smaller dataset with defined end date.
6	Typically funded by non-commercial entities.	Funded by both commercial and non-commercial entities.
7	Always an observational study design.	Use observational or interventional study design. Not all observational studies are registry studies.
8	Registry study can be considered a post-market study.	Post-market study includes but not limited to registry study.

Medical Device Registries: A Growing Footprint Across Asia-Pacific and MENA

- <u>Current Worldwide Prevalence</u>: Increasing evidence barriers in emerging markets will require local, real-world evidence focused on cost-effectiveness.
- <u>Emerging Markets</u>: Balance between budget neutrality and expanding patient access to therapies.

ORTHOPEDIC REGISTRIES: 204



CARDIOVASCULAR REGISTRIES: 1301

7

Clinical Registries: Key Objectives

- <u>Improve patient care</u> by providing granularity in the outcomes of medical device technologies: Impact on best practices with health care professionals, and on facility care pathways.
- <u>Facilitate patient access</u> to technology/therapy adoption: Regulatory, reimbursement dossiers and buttress informed coverage decisions.
- <u>Evaluate the "real world" safety</u> and/or effectiveness of medical technologies beyond randomized controlled clinical trials or other clinical study paradigms.
- Meet regulatory requirements for <u>post-market data surveillance</u> as a quality gate as regards patient safety.



Medical Device Registries: Objectives

- **1.** Improve patient care by providing granularity in the outcomes of medical device technologies, health care professionals, facilities, and care pathways.
- 2. Facilitate patient access to required diagnostics and therapies by collecting actionable data elements to support regulatory and reimbursement dossiers.
- **3.** Obtain local, credible and readily verifiable data to support coverage decisions and the development of value messaging tools.
- 4. Evaluate the "real world" safety and/or effectiveness of medical technologies beyond investigational, randomized controlled clinical trials or other clinical study paradigms.
- 5. Meet regulatory requirements for post-market data surveillance.
- 6. Reduce pre-and post-market requirements for data collection by providing regulators with an alternative method for medical device performance surveillance.
- 7. Provide an accurate assessment in the comparative effectiveness of different medical technologies for a given disease state.
- 8. Develop additional hypotheses for future evaluation in investigational, controlled medical device trials.
- **9.** Provide background relevant data in the development or assessment of patient care guidelines (level of evidence procedural indications or appropriate use criteria) that characterize best clinical practices for specific disease states.

Asia-Pacific/MENA-Specific Considerations Mandating Need for a Device Registry Consensus Document

- Increasing <u>local</u> evidence thresholds to inform regulatory and/or reimbursement decisions by governments.
- Recognition by authorities for need to capture local data that accurately reflects region/country-specific disease prevalence, and anatomic/physiologic population-specific variation.
- Address region-specific capability gaps in medical device registry development, implementation, and maintenance.
- Advocate for and implement a consistent standard in medical device registry governance and acquisition of quality of data.



APACMed/MTAA/Mecomed Medical Device Registry Consensus Statement:

Addressing the Region-Specific Paradigm Shift in Local Evidence Thresholds

- APACMed/MTAA/Mecomed support principles of evidence-based medicine that support medical technology access to patients.
- Provide a perspective on evolving region-specific geopolitical trends in healthcare utilization that support a growing paramount role for Medical Devices Registries in our region.
- To characterize elements critical to the development, implementation, and maintenance of medical device registries (concordant with ISO-14155 GCP): Ensure appropriate adjudication of quality data by providers, payers, patients, policymakers and other interested stakeholders.
- Serve as a regional reference standard for all stakeholders to ensure uniformity and agreement with best practices.

How to Leverage this Consensus Statement with Internal Stakeholders

- Increase Awareness in your Firm of Registries as being an evolving critical component to "Market Access" Strategy in our Region
 <u>Broad Audience</u>: RA, MA, Clinical, HE&R, Senior Leadership Team
- <u>Position the Consensus Statement as a Reference Guide</u> to appropriate internal stakeholders involved in Clinical Strategy
- <u>Educate Appropriate Internal Functions</u> with this Webinar Conference Series



How to Leverage this Consensus Statement with **External** Stakeholders

Facilitate the development of evidence to support our technologies

• Registries data will facilitate patient's access to new technologies

Engage with Policy Makers

- Position the Consensus Statement as a Reference Guide to Policy Makers to shape a more equitable and standardized environment for Medical Device Registry.
- Educate Appropriate Policy Makers who have limited experience with Medical Device and Diagnostics with this Webinar Conference Series.

Educate Clinical Stakeholders

 Medical Professional Societies and/or Health Care Professionals who have Limited Experience in Registry Development, Implementation, and Maintenance.



QUESTIONS & ANSWERS





APACMed Medical Device Registry Webinar Series: Next Steps

WEBINAR Two [6th April, 2017]

Medical Device Registry Guiding Principles

WEBINAR Three [7th June, 2017]

Future of Medical Device Registries



